miR-135b和LZTS1 mRNA HE4 mRNA在卵巢癌中的表达及临床意义

doi:10.3969/j.issn.1006-6233.2021.09.011

摘要
图/表
参考文献
相关文章 (14)

全文: PDF (1421 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 观察微小RNA-135b(miR-135b)、亮氨酸拉链肿瘤抑制基因1(LZTS1)信使核糖核酸(mRNA)、人附睾蛋白4(HE4)mRNA在卵巢癌中的表达水平及临床意义。方法: 选取2018年1月至2020年11月本院接收的56例卵巢癌患者,收集手术切除的卵巢癌组织及其对应的癌旁组织。实时荧光定量PCR法检测两组卵巢组织中miR-135b、LZTS1 mRNA、HE4 mRNA的表达水平;分析卵巢癌组织中miR-135b、LZTS1 mRNA、HE4 mRNA表达水平与卵巢癌临床病理特征的关系及miR-135b、LZTS1 mRNA及HE4 mRNA表达水平对卵巢癌的诊断价值。结果: 卵巢癌组miR-135b、HE4 mRNA表达水平均明显高于癌旁组(P均<0.05),LZTS1 mRNA表达水平明显低于癌旁组(P<0.05);卵巢癌组织中miR-135b、LZTS1 mRNA、HE4 mRNA表达水平与卵巢癌患者肿瘤分化程度、TNM分期及淋巴结转移相关(P均<0.05);miR-135b、LZTS1 mRNA、HE4 mRNA对卵巢癌诊断的曲线下面积(AUC)分别为0.781、0.755、0.773,对应截断值分别为1.25、0.87、1.20,此时对应灵敏度分别为74.5%、76.4%、72.7%,特异度分别为77.2%、72.9%、77.2%;三者联合诊断卵巢癌的AUC为0.943,其灵敏度、特异度分别为90.9%、84.2%。结论: 卵巢癌患者卵巢癌组织中miR-135b、HE4 mRNA呈高表达,LZTS1 mRNA呈低表达,miR-135b、LZTS1 mRNA、HE4 mRNA对卵巢癌有一定诊断价值,三者联合可有效提高对卵巢癌的诊断效能。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：微小RNA-135b, 亮氨酸拉链肿瘤抑制基因1, 人附睾蛋白4, 卵巢癌

Abstract：Objective: To observe the expression level and clinical significance of microRNA-135b (miR-135b), leucine zipper tumor suppressor gene 1 (LZTS1) messenger RNA (mRNA), human epididymal protein 4 (HE4) mRNA in ovarian cancer. Methods: 56 patients with ovarian cancer in our hospital from January 2018 to November 2020 were selected, and the ovarian cancer tissues and their corresponding adjacent tissues were collected. The expression levels of miR-135b, LZTS1 mRNA and HE4 mRNA in ovarian tissues of the two groups were detected by real time fluorescent quantitative PCR; the relationships between the expressions of miR-135b, LZTS1 mRNA, HE4 mRNA and the clinicopathological features of ovarian cancer were analyzed; and the diagnostic values of expression levels of miR-135b, LZTS1 mRNA and HE4 mRNA in ovarian cancer were analyzed. Results: The expression levels of miR-135b and HE4 mRNA in ovarian cancer group were significantly higher than those in adjacent group (P<0.05), and the expression level of LZTS1 mRNA was significantly lower than that in adjacent group (P<0.05); the expression levels of miR-135b, LZTS1 mRNA and HE4 mRNA in ovarian cancer were correlated with tumor differentiation, TNM stage and lymph node metastasis (P<0.05); the area under curve (AUC) of miR-135b, LZTS1 mRNA and HE4 mRNA in the diagnosis of ovarian cancer were 0.781, 0.755 and 0.773, respectively, the corresponding cutoff values were 1.25, 0.87 and 1.20, respectively, at this time, the corresponding sensitivities were 74.5%, 76.4% and 72.7%, and the specificities were 77.2%, 72.9% and 77.2%, respectively; the AUC of the combined diagnosis of ovarian cancer was 0.943, and the sensitivity and specificity were 90.9% and 84.2% respectively. Conclusions: MiR-135b and HE4 mRNA are highly expressed in ovarian cancer, LZTS1 mRNA is lowly expressed, miR-135b, LZTS1 mRNA and HE4 mRNA have certain diagnostic value for ovarian cancer, and the combination of them can effectively improve the diagnostic efficacy for ovarian cancer.

Key words： microRNA-135b Leucine zipper tumor suppressor 1 Human epididymal protein 4 Ovarian cancer

基金资助:湖北省卫生健康委员会科研项目,(编号:WJ2019M143)

通讯作者: 章阳

引用本文:

章品, 冯国琴, 程文凤, 章阳. miR-135b和LZTS1 mRNA HE4 mRNA在卵巢癌中的表达及临床意义[J]. 河北医学, 2021, 27(9): 1454-1459.
ZHANG Pin, et al. Expressions and Clinical Significance of MiR-135b LZTS1 mRNA and HE4 mRNA in Ovarian Cancer. HeBei Med, 2021, 27(9): 1454-1459.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2021.09.011 或 http://www.hbyxzzs.cn/CN/Y2021/V27/I9/1454

[1] Octavio BL,Asunción AM,Carmela BG,et al.Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients:real-life study[J].Oncol Pharm Pract,2021,27(2):268~278.
[2] Gu Y,Zhang S.High-throughput sequencing identification of differentially expressed microRNAs in metastatic ovarian cancer with experimental validations[J].Cancer Cell Int,2020,20(1):1~15.
[3] 汪萍萍,张青冬,冯晓萍,等.miR-135b在卵巢上皮癌中的表达及意义[J].中华实用诊断与治疗杂志,2018,32(8):733~735.
[4] He Y,Liu X.The tumor-suppressor gene LZTS1 suppresses hepatocellular carcinoma proliferation by impairing PI3K/Akt pathway[J].Biomed Pharmacother,2015,76(12):141~146.
[5] Yang WL,Lu Z,Guo J,et al.Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer[J].Cancer,2020,126(4):725~736.
[6] 中华人民共和国国家卫生健康委员会.卵巢癌诊疗规范(2018年版)[J].肿瘤综合治疗电子杂志,2019,5(2):87~96.
[7] Arend RC,Jackson-Fisher A,Jacobs IA,et al.Ovarian cancer:new strategies and emerging targets for the treatment of patients with advanced disease[J].Cancer Biol Ther,2021,22(2):89~105.
[8] Aziz NB,Mahmudunnabi RG,Umer M,et al.MicroRNAs in ovarian cancer and recent advances in the development of microRNA-based biosensors[J].Analyst,2020,145(6):2038~2057.
[9] 乐珍,沈君菁,黄启涛,等.miR-135b通过靶向FOXO1促进子宫内膜癌细胞的增殖[J].南方医科大学学报,2016,36(5):675~680.
[10] Lv ZD,Xin HN,Yang ZC,et al.miR-135b promotes proliferation and metastasis by targeting APC in triple-negative breast cancer[J].Cell Physiol,2019,234(7):10819~10826.
[11] Hou X,Niu Z,Liu L,et al.miR-1207-5p regulates the sensitivity of triple-negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression[J].Oncol Lett,2019,17(1):990~998.
[12] 张永久,王江,郭红,等.qRT-PCR法分析甲状腺乳头状癌FEZ1/LZTS1基因异常表达研究[J].西北国防医学杂志,2016,37(10):634~637.
[13] Olasz EB,Seline LN,Schock AM,et al.MicroRNA-135b regulates leucine zipper tumor suppressor 1 in cutaneous squamous cell carcinoma[J].PLoS One,2015,10(5):25412~25418.
[14] Ohkuma R,Yada E,Ishikawa S,et al.High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer[J].Int Oncol,2021,58(1):57~69.
[15] Luo CH,Zhao M,Tang YX,et al.Increased HE4 mRNA expression correlates with high level of eIF3a mRNA and better survival in women with epithelial ovarian cancer[J].Cancer,2018,9(6):1088~1095.